April 23, 2026

Regeneron strikes drug pricing deal with Trump administration

Regeneron will reduce U.S. drug prices and offer its new hearing-loss gene therapy for free to eligible patients after FDA approval.
This deal is part of President Trump's broader strategy to tie U.S. drug prices to those in other countries, exempting companies from tariffs for three years.
The FDA recently approved Regeneron's Otarmeni therapy, which addresses a rare genetic condition affecting hearing, potentially generating $130 million in peak sales.